UroGen Pharma Ltd. — Director's Dealing 2022

Sep 2, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-08-31

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-31	Ordinary Shares	M	8333	—	Acquired	15782	Direct
2022-08-31	Ordinary Shares	S	3606	$7.21	Disposed	12176	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-31	Restricted Stock Units	$	M	8333	Disposed		Ordinary Shares (8333)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units

F3: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vest in three equal annual installments on November 30, 2021, August 31, 2022 and August 31, 2023.